AEON Biopharma, Inc. - 10-Q Filing

AEON Biopharma reports Q3 2026 financial results featuring complex fair value measurements for warrant liabilities and contingent considerations.

SEC EDGAR ·

Tickers: $AEON

Read the full article at SEC EDGAR

More Regulatory news